SCHEMBL3097161

SCHEMBL3097161

CCN(C(=O)C(Cc1ccc(OC)c(OC)c1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.46
LDHA P00338 1/20 0.44
LARS1 Q9P2J5 1/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MMP1 P03956 2/20 0.42
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42
ADAM17 P78536 1/20 0.42
RAPGEF3 O95398 1/20 0.42
NPC1 O15118 1/20 0.42
MITF O75030 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
KAT6A Q92794 2/20 0.41
TAS2R14 Q9NYV8 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
F2 P00734 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091842 0.92 LARS1 (0.43) PDE4DLARS1ALDH1A1KMT2AKDM4E
SCHEMBL3087753 0.92 LARS1 (0.43) PDE4DLARS1ALDH1A1KMT2AKDM4E
SCHEMBL3100322 0.90 KDM4E (0.49) LDHALARS1ALDH1A1KMT2AKDM4E
SCHEMBL3085743 0.90 RAPGEF3 (0.42) LARS1ALDH1A1KMT2AKDM4EMMP1
SCHEMBL3089238 0.90 ALDH1A1 (0.43) LARS1ALDH1A1KMT2AMMP1MMP9
SCHEMBL14999961 0.89 PDE4D (0.48) PDE4DLDHALARS1ALDH1A1KMT2A
SCHEMBL3097466 0.88 KDM4E (0.47) LARS1ALDH1A1KMT2AKDM4EMMP1
SCHEMBL3092629 0.87 POLB (0.55) LARS1ALDH1A1KMT2AKDM4ERAPGEF3
SCHEMBL3093111 0.85 LARS1 (0.46) LARS1KMT2AMMP1MMP9MMP13
SCHEMBL3086151 0.85 SLC16A3 (0.47) LARS1POLBF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 PDE4D 3826/4885LDHA 723/4885LARS1 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.